These findings indicate that CAV-1 treatment reduced lipid accumulation, reducing lipid peroxidative production and the inflammatory activity of vascular cells, and protected tubular nephrocalcinosis and pyelonephritis in the hypercholesterol-affected target organs, the kidneys. The gene discussed is CAV1; the disease is nephrocalcinosis.